Development of Hyperplasias, Preneoplasias, and Mammary Tumors in MMTV-c-erbB-2 and MMTV-TGFα Transgenic Rats

Por Davies, Barry R., Platt-Higgins, Angela M., Schmidt, Gunter, Rudland, Philip S.
Publicado em 1999

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Por Sommer, Eeva M., Dry, Hannah, Cross, Darren, Guichard, Sylvie, Davies, Barry R., Alessi, Dario R.
Publicado em 2013

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

Por Fox, Emily M, Kuba, María Gabriela, Miller, Todd W, Davies, Barry R, Arteaga, Carlos L
Publicado em 2013

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

Por De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu
Publicado no Oncotarget (2016)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer...

Por CRAFTER, CLAIRE, VINCENT, JOHN P., TANG, ERIC, DUDLEY, PHILLIPPA, JAMES, NEIL H., KLINOWSKA, TERESA, DAVIES, BARRY R.
Publicado no Int J Oncol (2015)

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

Por Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.
Publicado no Dis Model Mech (2018)

Transfection of S100A4 Produces Metastatic Variants of an Orthotopic Model of Bladder Cancer

Por Levett, Diana, Flecknell, Paul A., Rudland, Philip S., Barraclough, Roger, Neal, David E., Mellon, J. Kilian, Davies, Barry R.
Publicado em 2002

Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells

Por Dickstein, Rian J., Nitti, Giovanni, Dinney, Colin P., Davies, Barry R., Kamat, Ashish M., McConkey, David J.
Publicado em 2012

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

Por Lynch, James T., McEwen, Robert, Crafter, Claire, McDermott, Ultan, Garnett, Mathew J., Barry, Simon T., Davies, Barry R.
Publicado no Oncotarget (2016)

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

Por Feng, Shu, Shao, Longjiang, Castro, Patricia, Coleman, Ilsa, Nelson, Peter S, Smith, Paul D, Davies, Barry R, Ittmann, Michael
Publicado no Oncotarget (2016)

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia

Por Chapman, Elinor A., Oates, Melanie, Mohammad, Ishaque S., Davies, Barry R., Stockman, Paul K., Zhuang, Jianguo, Pettitt, Andrew R.
Publicado no Oncotarget (2017)

A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

Por Yates, James W T, Holt, Sarah V, Logie, Armelle, Payne, Kirsty, Woods, Karen, Wilkinson, Robert W, Davies, Barry R, Guichard, Sylvie M
Publicado no Br J Pharmacol (2017)

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Por Ezell, Scott A., Wang, Suping, Bihani, Teeru, Lai, Zhongwu, Grosskurth, Shaun E., Tepsuporn, Suprawee, Davies, Barry R., Huszar, Dennis, Byth, Kate F.
Publicado no Oncotarget (2016)

Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment

Por Searle, Emma J, Telfer, Brian A, Mukherjee, Debayan, Forster, Duncan M, Davies, Barry R, Williams, Kaye J, Stratford, Ian J, Illidge, Tim M
Publicado no EMBO Mol Med (2017)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

Por Butler, Dominika E., Marlein, Christopher, Walker, Hannah F., Frame, Fiona M., Mann, Vincent M., Simms, Matthew S., Davies, Barry R., Collins, Anne T., Maitland, Norman J.
Publicado no Oncotarget (2017)

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

Por O'Neill, Daniel, Jones, Dominic, Wade, Mark, Grey, James, Nakjang, Sirintra, Guo, Wenrui, Cork, David, Davies, Barry R., Wedge, Steve R., Robson, Craig N., Gaughan, Luke
Publicado no Oncotarget (2015)

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Por Li, Jing, Davies, Barry R, Han, Sufang, Zhou, Minhua, Bai, Yu, Zhang, Jingchuan, Xu, Yan, Tang, Lily, Wang, Huiying, Liu, Yuan Jie, Yin, Xiaolu, Ji, Qunsheng, Yu, De-Hua
Publicado em 2013

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Por Green, Tim P., Fennell, Mike, Whittaker, Robin, Curwen, Jon, Jacobs, Vivien, Allen, Jack, Logie, Armelle, Hargreaves, Judith, Hickinson, D. Mark, Wilkinson, Robert W., Elvin, Paul, Boyer, Brigitte, Carragher, Neil, Plé, Patrick A., Bermingham, Alun, Holdgate, Geoffrey A., Ward, Walter H.J., Hennequin, Laurent F., Davies, Barry R., Costello, Gerard F.
Publicado no Mol Oncol (2009)

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-a...

Por Fu, Xiaoyong, Creighton, Chad J, Biswal, Nrusingh C, Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Gladys, Nardone, Agostina, Karlin, Kristen L, Westbrook, Thomas F, Heiser, Laura M, Anur, Pavana, Spellman, Paul, Guichard, Sylvie M, Smith, Paul D, Davies, Barry R, Klinowska, Teresa, Lee, Adrian V, Mills, Gordon B, Rimawi, Mothaffar F, Hilsenbeck, Susan G, Gray, Joe W, Joshi, Amit, Osborne, C Kent, Schiff, Rachel
Publicado no Breast Cancer Res (2014)